Q & A with Principal Investigator
We reviewed the initiatives of twenty-one research-based global biopharmaceutical companies to assess their strategies for improving access and the quality of evidence on the impact of their initiatives.
Dr. Richard Laing’s presentation on the Evaluation of Novartis Access at the World Health Assembly in Geneva, Switzerland, on May 25th, 2016 (Full)
Dr. Richard Laing’s presentation on the Evaluation of Novartis Access at the Ecumenical Pharmaceutical Network forum in Tübingen, Germany, on May 19th, 2016 (Abbreviated)
All Topics (April 22 through June 30)
There are no events in All Topics during the specified time period.